Altretamine (BioDeep_00000026965)

 

Secondary id: BioDeep_00000014950

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine

化学式: C9H18N6 (210.1593)
中文名称: 2,4,6-三(二甲氨基)均三嗪
谱图信息: 最多检出来源 Homo sapiens(blood) 29.35%

分子结构信息

SMILES: CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
InChI: InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3

描述信息

Altretamine is only found in individuals that have used or taken this drug. It is an alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. [PubChem]The precise mechanism by which altretamine exerts its cytotoxic effect is unknown although it is classified as an alkylating anti-neoplastic agent. Through this mechanism, the drug is metabolized into alkylating agents by N-demethylation. These alkylating species consequently damage tumor cells.
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents
D009676 - Noxae > D000477 - Alkylating Agents
D000970 - Antineoplastic Agents

同义名列表

23 个代谢物同义名

N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; Rhône-poulenc rorer brand OF altretamine; Rhône poulenc rorer brand OF altretamine; 2,4,6-Tris(dimethylamino)-S-triazine; MGI pharma brand OF altretamine; Wassermann brand OF altretamine; Altretamine wassermann brand; Chiesi brand OF altretamine; Bellon brand OF altretamine; Altretamine bellon brand; Altretamine chiesi brand; HEXAMETHYLMELAMINE; Altretaminum; Altretamina; altretamine; Hexinawas; Hexastat; Hexalen; Hemel; HTM; HXM; HMM



数据库引用编号

13 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Ritutama Ghosh, Sonya K Bharathkar, Nand Kishore. Anticancer altretamine recognition by bovine serum albumin and its role as inhibitor of fibril formation: Biophysical insights. International journal of biological macromolecules. 2019 Oct; 138(?):359-369. doi: 10.1016/j.ijbiomac.2019.07.093. [PMID: 31323265]
  • Nishikant Wase, Boqiang Tu, James W Allen, Paul N Black, Concetta C DiRusso. Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae. Plant physiology. 2017 Aug; 174(4):2146-2165. doi: 10.1104/pp.17.00433. [PMID: 28652262]
  • Bina Gidwani, Amber Vyas. Pharmacokinetic study of solid-lipid-nanoparticles of altretamine complexed epichlorohydrin-β-cyclodextrin for enhanced solubility and oral bioavailability. International journal of biological macromolecules. 2017 Aug; 101(?):24-31. doi: 10.1016/j.ijbiomac.2017.03.047. [PMID: 28315435]
  • Bina Gidwani, Amber Vyas. Preparation, characterization, and optimization of altretamine-loaded solid lipid nanoparticles using Box-Behnken design and response surface methodology. Artificial cells, nanomedicine, and biotechnology. 2016; 44(2):571-80. doi: 10.3109/21691401.2014.971462. [PMID: 25363752]
  • Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
  • Dongsun Park, Tae Kyun Kim, Young Jin Choi, Sun Hee Lee, Dae-Kwon Bae, Goeun Yang, Yun-Hui Yang, Seong Soo Joo, Ehn-Kyoung Choi, Byeongwoo Ahn, Jong-Choon Kim, Kil-Soo Kim, Yun-Bae Kim. Increased nephrotoxicity after combined administration of melamine and cyanuric Acid in rats. Laboratory animal research. 2011 Mar; 27(1):25-8. doi: 10.5625/lar.2011.27.1.25. [PMID: 21826156]
  • Jukui Sun, Yingjie Deng, Siling Wang, Jinna Cao, Xiaofei Gao, Xiaodong Dong. Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation. Drug delivery. 2010 Apr; 17(3):164-70. doi: 10.3109/10717541003667764. [PMID: 20196698]
  • M L Rothenberg, P Y Liu, S Wilczynski, E V Hannigan, S A Weiner, G R Weiss, V J Hunter, J A Chapman, A Tiersten, P C Kohler, D S Alberts. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecologic oncology. 2001 Aug; 82(2):317-22. doi: 10.1006/gyno.2001.6274. [PMID: 11531286]
  • R T Zon, J McClean, D Helman, R Ansari, J Picus, A Sandler, S D Williams, P J Loehrer. Altretamine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group trial. Investigational new drugs. 2001; 19(3):229-31. doi: 10.1023/a:1010620601431. [PMID: 11561679]
  • G J Rustin, A E Nelstrop, M Crawford, J Ledermann, H E Lambert, R Coleman, J Johnson, H Evans, S Brown, W Oster. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Jan; 15(1):172-6. doi: 10.1200/jco.1997.15.1.172. [PMID: 8996139]
  • I K Barker, S M Crawford, A F Fell. Determination of altretamine in human plasma with high-performance liquid chromatography. Journal of chromatography. B, Biomedical applications. 1994 Oct; 660(1):121-6. doi: 10.1016/0378-4347(94)00268-1. [PMID: 7858704]
  • M M Ames. Hexamethylmelamine: pharmacology and mechanism of action. Cancer treatment reviews. 1991 Mar; 18 Suppl A(?):3-14. doi: 10.1016/0305-7372(91)90019-v. [PMID: 1904306]
  • L A Hansen, T E Hughes. Altretamine. DICP : the annals of pharmacotherapy. 1991 Feb; 25(2):146-52. doi: 10.1177/106002809102500209. [PMID: 1905441]
  • M M Ames, R L Richardson, J S Kovach, C G Moertel, M J O'Connell. Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation. Cancer research. 1990 Jan; 50(1):206-10. doi: NULL. [PMID: 2104537]
  • J Dubois, G Atassi, M Hanocq, F Abikhalil. Tumor pharmacokinetics of hexamethylmelamine in CDF1 mice bearing P388 leukemia. Anticancer research. 1989 Jan; 9(1):255-9. doi: NULL. [PMID: 2495757]
  • M Slavik, T R Narasimhan, C Riley, J Slavik. Changes in serum copper and zinc during treatment with anticancer drugs interfering with pyridoxal phosphate. Advances in experimental medicine and biology. 1989; 258(?):235-42. doi: 10.1007/978-1-4613-0537-8_21. [PMID: 2516708]
  • S Bielack, J Knop, G Delling, K Winkler. [Scintigraphic follow-up of osteosarcoma during neoadjuvant chemotherapy. Results of the cooperative osteosarcoma study of the Society for Pediatric Oncology]. Nuklearmedizin. Nuclear medicine. 1988 Dec; 27(6):237-41. doi: NULL. [PMID: 2464164]
  • W W ten Bokkel Huinink. Current status of chemotherapy for ovarian carcinoma. European journal of cancer & clinical oncology. 1988 Apr; 24(4):583-5. doi: 10.1016/0277-5379(88)90284-2. [PMID: 3133217]
  • C Neef, I de Voogd-van der Straaten. An interaction between cytostatic and anticonvulsant drugs. Clinical pharmacology and therapeutics. 1988 Apr; 43(4):372-5. doi: 10.1038/clpt.1988.45. [PMID: 3128415]
  • J Dubois, G Atassi, M Hanocq, F Abikhalil. Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors. Cancer chemotherapy and pharmacology. 1988; 22(4):282-8. doi: 10.1007/bf00254232. [PMID: 3139314]
  • I L Gordon, R Kar, R W Opfell, A G Wile. Pharmacokinetics of hexamethylmelamine in intralipid following hepatic regional administration in rabbits. Cancer research. 1987 Oct; 47(19):5070-3. doi: NULL. [PMID: 3113728]
  • J P Neijt, W W ten Bokkel Huinink, M E van der Burg, A T van Oosterom, P H Willemse, A P Heintz, M van Lent, J B Trimbos, J Bouma, J B Vermorken. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1987 Aug; 5(8):1157-68. doi: 10.1200/jco.1987.5.8.1157. [PMID: 3114434]
  • I R Judson, C J Rutty, G Abel, M A Graham. Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity. British journal of cancer. 1986 May; 53(5):601-6. doi: 10.1038/bjc.1986.102. [PMID: 3087399]
  • A Paolini, M D'Incalci. Effect of phenobarbital pretreatment on the metabolism and antitumor activity of hexamethylmelamine. Cancer treatment reports. 1986 Apr; 70(4):513-6. doi: NULL. [PMID: 3084083]
  • J Dubois, G Atassi, M Hanocq, F Abikhalil. Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration. Cancer chemotherapy and pharmacology. 1986; 18(3):226-30. doi: 10.1007/bf00273391. [PMID: 3100080]
  • A D Wickes, S B Howell. Pharmacokinetics of hexamethylmelamine administered via the Ip route in an oil emulsion vehicle. Cancer treatment reports. 1985 Jun; 69(6):657-62. doi: NULL. [PMID: 3926309]
  • P J Klippert, A Hulshoff, G A Hofman, J Noordhoek. First-pass metabolism of pentamethylmelamine in the rat liver. Cancer research. 1985 Mar; 45(3):983-6. doi: NULL. [PMID: 3918792]
  • K J Miller, R M McGovern, M M Ames. Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines. Cancer chemotherapy and pharmacology. 1985; 15(1):49-53. doi: 10.1007/bf00257294. [PMID: 3924426]
  • C M Richman, M M Makii, P A Weiser, A L Herbst. The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia. American journal of hematology. 1984 May; 16(4):313-23. doi: 10.1002/ajh.2830160402. [PMID: 6426295]
  • D Ross, S P Langdon, A Gescher, M F Stevens. Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism. Biochemical pharmacology. 1984 Apr; 33(7):1131-6. doi: 10.1016/0006-2952(84)90525-2. [PMID: 6424683]
  • A E Bogden, W Griffin, S D Reich, M E Costanza, W R Cobb. Predictive testing with the subrenal capsule assay. Cancer treatment reviews. 1984 Mar; 11 Suppl A(?):113-24. doi: 10.1016/0305-7372(84)90050-1. [PMID: 6428738]
  • J A Molello, S D Barnard, D J Thompson. Pancreatic beta cell vacuolation in rats after oral administration of hexamethylmelamine. Toxicology and applied pharmacology. 1984 Feb; 72(2):255-61. doi: 10.1016/0041-008x(84)90310-7. [PMID: 6420937]
  • P J Klippert, A Hulshoff, M J Mingels, G Hofman, J Noordhoek. Low oral bioavailability of hexamethylmelamine in the rat due to simultaneous hepatic and intestinal metabolism. Cancer research. 1983 Jul; 43(7):3160-4. doi: NULL. [PMID: 6406053]
  • L Morasca, E Erba, M Vaghi, C Ghelardoni, C Mangioni, C Sessa, F Landoni, S Garattini. Clinical correlates of in vitro drug sensitivities of ovarian cancer cells. British journal of cancer. 1983 Jul; 48(1):61-8. doi: 10.1038/bjc.1983.157. [PMID: 6409137]
  • D J Stewart, J A Benvenuto, M Leavens, R G Smith, F Cabanillas, R S Benjamin, T L Loo. Human central nervous system pharmacology of pentamethylmelamine and its metabolites. Journal of neuro-oncology. 1983; 1(4):357-64. doi: 10.1007/bf00165719. [PMID: 6432969]
  • M Giannattasio, R Rizzi, P Coratelli, A Restaino, L Selvaggi, R Ferreri, E Orlando, G M Ierardi, A Granata, S Bettocchi. Use of cis-platinum in the treatment of ovarian carcinoma. Clinical results and evaluation of nephrotoxicity. European journal of gynaecological oncology. 1983; 4(1):41-3. doi: NULL. [PMID: 6407837]
  • E Garattini, T Colombo, M G Donelli, P Catalani, M Bianchi, M D'Incalci, C Pantarotto. Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma. Cancer chemotherapy and pharmacology. 1983; 11(1):51-5. doi: 10.1007/bf00257418. [PMID: 6411375]
  • J R Muindi, D R Newell, I E Smith, K R Harrap. Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies. British journal of cancer. 1983 Jan; 47(1):27-33. doi: 10.1038/bjc.1983.3. [PMID: 6401427]
  • T Colombo, M Broggini, A Gescher, M D'Incalci. Routes of elimination of hexamethylmelamine and pentamethylmelamine in the rat. Xenobiotica; the fate of foreign compounds in biological systems. 1982 May; 12(5):315-21. doi: 10.3109/00498258209052471. [PMID: 6814076]
  • C Brindley, A Gescher, S P Langdon, M Broggini, T Colombo, M D'Incalci. Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamine. Biochemical pharmacology. 1982 Mar; 31(5):625-31. doi: 10.1016/0006-2952(82)90441-5. [PMID: 6805472]
  • M D'Incalci, P Farina, C Sessa, C Mangioni, S Garattini. Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers. Cancer treatment reports. 1982 Feb; 66(2):231-5. doi: NULL. [PMID: 6799199]
  • B G Durie, S E Salmon. The current status and future prospects of treatment for multiple myeloma. Clinics in haematology. 1982 Feb; 11(1):181-210. doi: NULL. [PMID: 6176381]
  • M Broggini, C Rossi, T Colombo, M D'Incalci. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice. Cancer treatment reports. 1982 Jan; 66(1):127-33. doi: NULL. [PMID: 6796267]
  • C J Rutty, D R Newell, J R Muindi, K R Harrap. The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse. Cancer chemotherapy and pharmacology. 1982; 8(1):105-11. doi: 10.1007/bf00292880. [PMID: 6807560]
  • D V Razis, E Poulakou, A Petounis, G Papadimitriou, P Kosmides, G Delides. Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine. Oncology. 1982; 39(4):205-8. doi: 10.1159/000225638. [PMID: 6806735]
  • B R Leyland-Jones, P E Deesen, E S Casper, C W Young. Specific determination of pentamethylmelamine and its demethylated metabolites in human plasma by high pressure liquid chromatography. Therapeutic drug monitoring. 1982; 4(2):185-90. doi: 10.1097/00007691-198206000-00005. [PMID: 6808715]
  • D C Ihde, J S Dutcher, R C Young, R S Cordes, A L Barlock, S M Hubbard, R B Jones, M R Boyd. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study. Cancer treatment reports. 1981 Sep; 65(9-10):755-62. doi: NULL. [PMID: 6791819]
  • M Broggini, T Colombo, M D'Incalci, M G Donnelli, A Gescher, S Garattini. Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice. Cancer treatment reports. 1981 Jul; 65(7-8):669-72. doi: NULL. [PMID: 6788370]
  • E S Casper, R J Gralla, G R Lynch, B R Jones, T M Woodcock, C Gordon, D P Kelsen, C W Young. Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion. Cancer research. 1981 Apr; 41(4):1402-6. doi: NULL. [PMID: 6783296]
  • J A Benvenuto, D J Stewart, R S Benjamin, T L Loo. Pharmacology of pentamethylmelamine in humans. Cancer research. 1981 Feb; 41(2):566-9. doi: NULL. [PMID: 6778609]
  • T Colombo, L Torti, M D'Incalci. Dose-dependent pharmacokinetics of PMM in the rat. Cancer chemotherapy and pharmacology. 1981; 5(3):201-3. doi: 10.1007/bf00258481. [PMID: 6794923]
  • A Hulshoff, J P Neijt, C F Smulders, A C van Loenen, H M Pinedo. Determination of hexamethylmelamine and metabolites in plasma or serum by gas-liquid chromatography with a nitrogen-sensitive detector. Journal of chromatography. 1980 Mar; 181(3-4):363-71. doi: 10.1016/s0378-4347(00)81139-1. [PMID: 6771300]
  • J S Dutcher, R B Jones, M R Boyd. A sensitive and specific assay for pentamethylmelamine in plasma: applicability to clinical studies. Cancer treatment reports. 1980 Jan; 64(1):99-104. doi: NULL. [PMID: 6769585]
  • M M Ames, G Powis, J S Kovach, R T Eagan. Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. Cancer research. 1979 Dec; 39(12):5016-21. doi: NULL. [PMID: 115586]
  • M D'Incalci, P Morazzoni, C Pantarotto. Gas chromatographic determination of hexamethylmelamine in mouse plasma. Analytical biochemistry. 1979 Nov; 99(2):441-9. doi: 10.1016/s0003-2697(79)80030-5. [PMID: 117725]
  • M M Ames, G Powis. Determination of pentamethylmelamine and hexamethylmelamine in plasma and urine by nitrogen-phosphorus gas-liquid chromatography. Journal of chromatography. 1979 Jun; 174(1):245-9. doi: 10.1016/s0021-9673(00)87062-4. [PMID: 121123]
  • M D'Incalci, G Bolis, C Mangioni, L Morasca, S Garattini. Variable oral absorption of hexamethylmelamine in man. Cancer treatment reports. 1978 Dec; 62(12):2117-9. doi: NULL. [PMID: 109196]
  • A J Cumber, W C Ross. Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility. Chemico-biological interactions. 1977 Jun; 17(3):349-57. doi: 10.1016/0009-2797(77)90097-7. [PMID: 407012]
  • B C Mitchley, S A Clarke, T A Connors, S M Carter, A M Neville. Chemotherapy of human tumors in T-lymphocyte-deficient mice. Cancer treatment reports. 1977 May; 61(3):451-62. doi: NULL. [PMID: 406045]
  • S S Legha, M Slavik, S K Carter. Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer. 1976 Jul; 38(1):27-35. doi: 10.1002/1097-0142(197607)38:1<27::aid-cncr2820380106>3.0.co;2-n. [PMID: 820422]